Sanofi: Lunsekimig Meets Primary, Key Secondary Endpoints In Phase 2 Respiratory Studies

Sanofi said Phase 2 studies of lunsekimig in two chronic respiratory diseases met primary and key secondary endpoints versus placebo and were well tolerated with an acceptable safety profile. Positive Phase 2 readouts de-risk the program and increase the likelihood of advancing to Phase 3, likely supporting a modest (low single-digit percent) positive move in Sanofi shares pending detailed results and regulatory planning.

Analysis

Sanofi said Phase 2 studies of lunsekimig in two chronic respiratory diseases met primary and key secondary endpoints versus placebo and were well tolerated with an acceptable safety profile. Positive Phase 2 readouts de-risk the program and increase the likelihood of advancing to Phase 3, likely supporting a modest (low single-digit percent) positive move in Sanofi shares pending detailed results and regulatory planning.